EMA Authorised: Fulvestrant Mylan (fulvestrant) — Mylan Pharmaceuticals Limited

View source ↗

Summary

Fulvestrant Mylan has been authorised in the EU for breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant Mylan (fulvestrant)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Mylan Pharmaceuticals Limited. Decision date: 08/06/2026